Company data sheet · Argenx
Argenx: from profit to nine straight losses.
- Industry
- Biological Products,
- Headquarters
- Netherlands
- Ticker
- ARGX (Nasdaq)
- Sources
- SEC filings (2017–2026), Stratrix's verified Decision Cases, market data and official economic statistics for Netherlands
- Data as of
- October 18, 2026
- From profit to nine straight losses. Argenx lost money every year from 2015 to 2023: $2.3 billion in all. 2024 was its first profit in ten years: $0.8 billion.
- Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 25844% in US dollars; the median among 586 large manufacturers grew 58%. It outgrew 99% of them.
- Still smaller than it was. Revenue reached $0 billion in 2023, 93% below its 2021 peak of $0.5 billion.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $0 billion | −$0 billion | |
| 2017 | $0 billion | −$0 billion | |
| 2018 | $0 billion | −$0.1 billion | |
| 2019 | $0.1 billion | −$0.2 billion | |
| 2020 | $0 billion | −$0.6 billion | |
| 2021 | $0.5 billion | −$0.4 billion | |
| 2022 | $0 billion | −$0.7 billion | |
| 2023 | $0 billion | −$0.3 billion |
As reported in its annual filings. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 6 measures for Netherlands, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.